Cargando…
Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial established that a stimulated C-peptide concentration ≥0.2 nmol/L at study entry among subjects with up to a 5-year diabetes duration is associated with favorable metabolic and clinical outcomes over the subsequent 7 years of follow-up. Herein we further...
Autores principales: | Lachin, John M., McGee, Paula, Palmer, Jerry P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900540/ https://www.ncbi.nlm.nih.gov/pubmed/24089509 http://dx.doi.org/10.2337/db13-0881 |
Ejemplares similares
-
Relationship of Glycated Albumin to Blood Glucose and HbA(1c) Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study
por: Nathan, David M., et al.
Publicado: (2014) -
Progression of Carotid Artery Intima-Media Thickness During 12 Years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
por: Polak, Joseph F., et al.
Publicado: (2011) -
Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial
por: Lachin, John M., et al.
Publicado: (2017) -
Skin Advanced Glycation End Products Glucosepane and Methylglyoxal Hydroimidazolone Are Independently Associated With Long-term Microvascular Complication Progression of Type 1 Diabetes
por: Genuth, Saul, et al.
Publicado: (2015) -
Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2008)